In conjunction with the merger, Candid has successfully raised over $370 million in capital from an extensive roster of investors, which includes a recently completed financing co-led by Venrock Healthcare Capital Partners, Fairmount, TCGX, and venBio Partners. Other notable healthcare investors supporting the company include Foresite Capital, Third Rock Ventures, Fidelity Management & Research Company, Samsara BioCapital, Qiming Venture Partners USA, OrbiMed, Boxer Capital, Redmile Group, Vida Ventures, Two River, Franklin Templeton, LifeSci Venture Partners, Mirae Asset Capital Life Science, Polaris Innovation Fund, Soleus Capital and other reputable institutional and mutual fund investors. This substantial financial backing highlights strong investor confidence in Candid’s purposeful approach and strategic vision, positioning the company for significant impact in bringing forth first-in-class therapies to patients with autoimmune diseases.
There are a lot of American startups funding deals that are creating buzz around the startup ecosystem. These are the growth-stage and early-stage deals...
eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced the close of a $191 million Series D financing. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney transplant. The funding will also be used to advance pipeline programs as well as scale production.
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, has received a $45 million milestone payment from Regeneron Pharmaceuticals, Inc., under the terms of its active collaboration to discover, develop and commercialize engineered Treg therapies for autoimmune diseases.
PsychoGenics, a leader in AI-enabled phenotypic drug discovery, has been awarded a Fast Track Small Business Innovation Research (SBIR) grant by NIMH, worth up to $3 million over four years.
Canada-based Aplantex, innovative Quebec-based startup specializing in extracting high-value plant molecules from its proprietary biomass, has secured $2.8 million CAD Financing led by Frederick Perrault, with participation of the Circular Innovation Fund (CIF) through its Acceleration Program, Cycle Momentum, Investissement Québec, and a number of angel investors. This funding will accelerate the development of the company’s strategic and production plan.
Diakonos Oncology Corp., a clinical-stage immuno-oncology company, announced the final closing of an oversubscribed seed financing of $11.4 million. The round was led by biotechnology investment firm Restem Group Inc., with participation from existing investors.
Seattle, WA-based Talus Bioscience, Gene regulator profiling in live cells for drug development Raises $11.2 Million in New Funding led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures.
Genedata AG (“Genedata”), a leading provider of software solutions for biopharmaceutical R&D, has been acquired by Danaher Corporation (NYSE: DHR) (“Danaher”), a leading global life sciences and diagnostics innovator.
Accenture has made a strategic investment, through Accenture Ventures, in Earli Inc., a biotechnology company that developed a novel approach to early cancer detection with a synthetic targeting platform that selectively reprograms cancer cells to reveal and destroy themselves.
